Baseline Productions News
News
0
Ticker
BSSP
ISIN
US0702491079
Baseline Productions Eulerpool News
Baseline Productions Stock News
Baseline Productions is being monitored by journalists and investors worldwide. We gather the latest Baseline Productions news here.
Baseline Productions Stock Press Releases
Baseline Productions regularly publishes news on the company's website that are relevant for investors.
Baseline Productions News 2026
This page contains all current news, analysis and press releases for Baseline Productions stock (BSSP, ISIN: US0702491079). This includes Eulerpool news, company analysis and official press releases. Data is updated regularly to provide investors with a complete overview of the latest developments at Baseline Productions.
Baseline Productions Stock
Baseline Productions Baseline Productions Inc develops mobile based hardware and software based products. The company focuses on commercialization of its proteins for cancer and infectious disease treatments. Its Irreversible Pepsin Fraction (IPF) technology activates the immune system to fight autoimmune diseases. IPF binds to T-cells and triggers Th1 responses that eliminate infected cells. The firm's lead compound is an IPF suspension for autoimmune disease treatment including cancer, cirrhosis, and Hepatitis C. The product IMMUNE-THERAPEUTIC PROTEIN (ITP) is a therapeutic protein derived from porcine pepsin, which is irreversible, modified, and fractionated to IPF sequence. The company sells its IPF platform technology and ITP product to healthcare providers and pharmaceutical companies. Healthcare providers use IPF for immune system activation in autoimmune disease treatment. Pharmaceutical companies purchase ITP for development into therapeutic applications. The target segments include medical institutions treating autoimmune conditions and drug manufacturers seeking novel protein-based therapies. ITP is specifically indicated for cancer, cirrhosis, and Hepatitis C treatment. Baseline Productions generates revenue through licensing IPF technology and selling ITP therapeutic protein. The IPF platform is sold as a technology solution to partners in the healthcare sector. ITP is marketed as a therapeutic product for direct sale to medical facilities. The company's primary customers are healthcare institutions and pharmaceutical firms interested in immune system-based treatments for autoimmune diseases and infectious conditions.